Get the Stockscreener App
0.6099
27.49%
0.1315
After Hours:
.63
0.0201
+3.30%
Adicet Bio Inc stock is traded at $0.6099, with a volume of 3.96M.
It is up +27.49% in the last 24 hours and up +17.29% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.4784
Open:
$0.5899
24h Volume:
3.96M
Relative Volume:
4.66
Market Cap:
$55.42M
Revenue:
$38.70M
Net Income/Loss:
$-117.88M
P/E Ratio:
-0.3588
EPS:
-1.7
Net Cash Flow:
$-92.84M
1W Performance:
-8.97%
1M Performance:
+17.29%
6M Performance:
-53.44%
1Y Performance:
-62.58%
1-Day Range:
$0.50
$0.6519
1-Week Range:
$0.472
$0.685
52-Week Range:
$0.4471
$1.73
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.6099 | 55.42M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Wedbush Comments on Adicet Bio’s Q3 Earnings (NASDAQ:ACET) - Defense World
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
What is Wedbush’s Estimate for Adicet Bio Q1 Earnings? - Defense World
Adicet Bio Reports Q1 2025 Results and Updates - TipRanks
Marshall Wace LLP Sells 104,894 Shares of Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Bluefield Daily Telegraph
Adicet Bio, Inc. (NASDAQ:ACET) Shares Acquired by JPMorgan Chase & Co. - Defense World
Reviewing Adicet Bio (NASDAQ:ACET) and HUTCHMED (NASDAQ:HCM) - Defense World
Renaissance Technologies LLC Has $882,000 Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Rating Increased to Hold at StockNews.com - Defense World
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - BioSpace
Adicet Bio Announces Oral Presentation Highlighting Preclinical Adi-270 Data At The American Society Of Gene And Cell Therapy 28Th Annual Meeting - marketscreener.com
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate - Yahoo Finance
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) Price Target at $7.50 - Defense World
JMP maintains Market Perform on Adicet Bio shares By Investing.com - Investing.com Canada
JMP maintains Market Perform on Adicet Bio shares - Investing.com
Adicet Bio (NASDAQ:ACET) Now Covered by StockNews.com - Defense World
Adicet Bio appoints Michael Grissinger to its board By Investing.com - Investing.com Canada
Adicet Bio Appoints Michael Grissinger to the Board of Directors - BioSpace
Adicet Bio appoints Michael Grissinger to its board - Investing.com
Adicet Bio Appoints Michael Grissinger to Board - TipRanks
Adicet Bio Appoints Michael Grissinger To The Board Of Directors - marketscreener.com
Adicet Bio Strengthens Board with Ex-Johnson & Johnson VP: Strategic Move for Cell Therapy Pioneer - Stock Titan
Norges Bank Acquires Shares of 429,550 Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio faces potential Nasdaq delisting over share price By Investing.com - Investing.com Nigeria
Adicet Bio faces potential Nasdaq delisting over share price - Investing.com
Virtu Financial LLC Purchases New Stake in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference - BioSpace
Adicet Bio Strengthens Team with Strategic Stock Options Package for Key New Hires - Stock Titan
Adicet Bio Reveals Next-Gen CAR-T Strategy for Autoimmune Diseases at Major Conference - Stock Titan
Adicet Bio, Inc. (NASDAQ:ACET) Receives $7.50 Consensus Target Price from Brokerages - Defense World
The Royal Office of H.H. Sheikh Ahmed Bin Faisal Al-Qassimi and ACET ($ACT) Drive Blockchain Payment Innovation in UAE’s $3.9 Billion USD Initiative - GlobeNewswire Inc.
Adicet Bio (NASDAQ:ACET) Earns “Buy” Rating from Guggenheim - The AM Reporter
Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
Guggenheim Reiterates Buy Rating for Adicet Bio (NASDAQ:ACET) - Defense World
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
ACET Stock Dips to 52-Week Low at $0.74 Amid Market Challenges - Investing.com
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):